EPAS1 and glioblastoma: HIF2α expression was also investigated as part of the Phase II Bevacizumab/Irinotecan recurrent GBM trial and patients with high carbonic anhydrase 9 (CA9) and HIF2α expression demonstrated the worst survival outcomes whereas, conversely, patients with low CA9 and HIF2α expression had the best clinical outcomes37.